NanoViricides NV-387 Clinical Development and Dual-Track Strategy FAQ
Summary
What is NanoViricides’ NV-387 drug candidate?
NV-387 is NanoViricides’ broad-spectrum antiviral drug candidate that uses nano-polymer micelle technology to bind and neutralize virus particles before they infect cells, targeting both MPox and respiratory viral infections including influenza, coronaviruses, and RSV.
What is the dual-track clinical development strategy mentioned in the report?
The dual-track strategy involves developing NV-387 for both MPox infections and respiratory viral infections simultaneously, with the company planning to initiate a Phase 2 trial for MPox while also developing the drug for respiratory viruses like COVID-19, influenza, and RSV.
When does NanoViricides plan to begin Phase 2 trials for NV-387?
The company plans to initiate a Phase 2 trial for MPox in Congo by late 2025 or early 2026, following completion of a Phase 1 safety and tolerability study in 2023, with ethics approval already secured.
How does NV-387’s technology work against viruses?
NV-387 uses nano-polymer micelle technology that binds and neutralizes virus particles before they can infect human cells, providing a broad-spectrum antiviral mechanism.
What potential funding opportunities are highlighted for NanoViricides?
The report highlights potential U.S. biodefense funding opportunities through BARDA (Biomedical Advanced Research and Development Authority) based on successful trial outcomes of NV-387.
What other drug candidates is NanoViricides developing besides NV-387?
NanoViricides is also developing NV-HHV-1 for shingles treatment, NV-CoV-2 and NV-CoV-2-R for COVID-19, and drugs against various other viral diseases including herpes, HIV, hepatitis C, rabies, dengue, and Ebola.
What is NanoViricides’ relationship with TheraCour Pharma?
NanoViricides has a Memorandum of Understanding with TheraCour Pharma for developing antiviral drugs based on TheraCour’s technology, holds exclusive sub-licensable field licenses, and licenses technology from TheraCour for specific viral applications as established since the company’s foundation in 2005.
What is the company’s current clinical focus?
NanoViricides is currently focused on advancing NV-387 into Phase 2 human clinical trials, though the company cannot project exact IND filing dates due to dependence on external collaborators and consultants.
What makes NV-387 different from other antiviral approaches?
NV-387’s nano-polymer micelle technology provides a broad-spectrum mechanism that neutralizes viruses before cellular infection, and the company has developed both standard and remdesivir-encapsulated versions for COVID-19 treatment.
Where can I find more information about this announcement?
The full press release can be viewed at https://ibn.fm/ib5Cg, and additional company information is available at https://www.investorbrandnetwork.com/clients/nanoviricides-inc/
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 253963